Brokerage firm Elara has initiated coverage on Alkem Laboratories, Eris Lifesciences, IPCA Laboratories and Mankind Pharma, with ratings ranging from Buy to Reduce. Alkem received a Buy rating; Eris and Mankind were both rated Accumulate, and IPCA was rated Reduce.
According to Elara, Alkem offers the strongest potential for margin recovery, while Eris and Mankind could benefit from portfolio expansion, acquisition synergies and deleveraging. On IPCA, Elara noted that the stock's 30% rally over the past three months has already priced in much of the expected margin recovery.
